Literature DB >> 626995

Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.

D L Ahmann, J H Edmonson, S Frytak, L K Kvols, H F Bisel, J Rubin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626995

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Boehler; Christoph Saely; Robert Strohal
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 2.  Chemotherapy of malignant melanoma.

Authors:  R S Benjamin
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 3.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

4.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

6.  Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.

Authors:  I G Ron; M J Inbar; M Gutman; O Merimsky; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.